LON:SYNC

Syncona (SYNC) Share Forecast, Price & News

GBX 151

-0.20 (-0.13%)

(As of 06/1/2023 ET)

Compare

Today's Range: 149
▼
155
50-Day Range: 145
▼
161.43
52-Week Range: 136.02
▼
213

Volume: 190,461 shs
Average Volume: 548,049 shs
Market Capitalization: £1.01 billion

P/E Ratio: 471.88
Dividend Yield: 1.06%
Price Target: N/A

Profile Chart Competitors Insider Trades Headlines Options Chain

About Syncona (LON:SYNC) Stock

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.

Receive SYNC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syncona and its competitors with MarketBeat's FREE daily newsletter.

SYNC Stock News Headlines

May 29, 2023 | finance.yahoo.com

SYNC.L - Syncona Limited

May 12, 2023 | msn.com

Chardan Capital Maintains Achilles Therapeutics Plc - ADR (ACHL) Buy Recommendation

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

April 19, 2023 | benzinga.com

OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress

April 13, 2023 | thetimes.co.uk

Biotech is in Britain’s DNA but still needs investment

April 4, 2023 | uk.finance.yahoo.com

Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics

April 4, 2023 | finance.yahoo.com

Mosaic Therapeutics Closes $28m Series A Funding and Appoints Brian Gladsden as CEO

March 22, 2023 | americanbankingnews.com

Syncona (LON:SYNC) Hits New 1-Year Low at $141.40

June 1, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

March 15, 2023 | benzinga.com

Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027; The increase in special drug designations to drive growth- Technavio

February 25, 2023 | thetimes.co.uk

NED Awards put talent on the agenda

February 14, 2023 | finance.yahoo.com

Bio-tech - UK Bio-Tech Companies Struggle with Sinking Investment

February 7, 2023 | thetimes.co.uk

Syncona catches cold from the chill afflicting biotech

February 3, 2023 | yahoo.com

Avado announces the FastFutures Movement with its 'Impact Report & Strategic Vision 2022'

February 3, 2023 | finanznachrichten.de

FastFutures & Avado: Avado announces the FastFutures Movement with its 'Impact Report & Strategic Vision 2022'

December 9, 2022 | lse.co.uk

Syncona portfolio firm hits 70% remission rate goal in leukaemia trial

November 21, 2022 | seekingalpha.com

Richard Francis is the new CEO and President of Teva Pharmaceutical

October 26, 2022 | barrons.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Applied Genetic Technologies Corporation (AGTC)

October 26, 2022 | nz.finance.yahoo.com

Syncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies Corporation

October 24, 2022 | msn.com

Wall Street Set to Open Higher as Markets Look to Build on Strong Week Ahead of PMI Data

October 24, 2022 | finance.yahoo.com

Small Eye-Focused Gene Therapy Company Applied Genetic Goes Private In $24M Deal

October 24, 2022 | msn.com

US Futures Higher, Looking to Build on Strong Week Ahead of PMI Data

October 24, 2022 | technews.tmcnet.com

AGTC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Applied Genetic Technologies Corporation Is Fair to Shareholders

October 15, 2022 | msn.com

Man shot to death in Desert Hot Springs; suspect in custody

September 1, 2022 | forbes.com

Investment Update: Wealth Manager Unveils Investment App

August 25, 2022 | forbes.com

Investment Update: Fund Manager Close To Losing FTSE-100 Status

August 18, 2022 | reuters.com

SYNCS.L - Syncona Ltd | Stock Price & Latest News | Reuters

See More Headlines

SYNC Price History

30 days | 90 days | 365 days | Advanced Chart

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Asset Management
Sub-Industry: N/A
Sector: Computer and Technology
Current Symbol: LON:SYNC
Previous Symbol: LON:BACT
CUSIP: N/A
CIK: N/A
Web: www.bacitltd.com
Phone: 17168531362
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX 0.32
Trailing P/E Ratio: 471.88
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: £212.36 million
Net Margins: 92.35%
Pretax Margin: N/A
Return on Equity: 16.86%
Return on Assets: 10.63%

Debt

Debt-to-Equity Ratio: 64.05
Current Ratio: 0.52
Quick Ratio: 0.53

Sales & Book Value

Annual Sales: £229.94 million
Price / Sales: 4.40
Cash Flow: GBX 128.57 per share
Price / Cash Flow: 1.17
Book Value: GBX 204 per share
Price / Book: 0.74

Miscellaneous

Outstanding Shares: 669,330,000
Free Float: N/A
Market Cap: £1.01 billion
Optionable: Optionable
Beta: 0.21

Key Executives

Mr. Thomas Henderson (Age 57)
Co-Founder & Non-Exec. Director

Dr. Martin Patrick Murphy Ph.D. (Age 55)
Chief Exec. Officer

Mr. John McDonald (Age 58)
Co-Founder

Mr. Rolf Kristian Berndtson Soderstrom ACA (Age 57)
BA, Chief Financial Officer

Dr. Christopher J. Hollowood Ph.D. (Age 48)
CIO & Managing Partner of Syncona Investment Management Ltd.

Ms. Annabel Clay
Head of Investor Relations

Mr. Andrew Cossar
Gen. Counsel of Syncona Investment Management Ltd.

Ms. Fenella Dernie
Exec. Officer

Mr. Edward Eliot Hodgkin DPhil (Age 60)
Sr. Partner

Ms. Nikki Padden Ph.D.
Head of Fin. at Syncona Investment Management Ltd.

Key Competitors

View All Competitors

SYNC Stock - Frequently Asked Questions

How have SYNC shares performed in 2023?: Syncona's stock was trading at GBX 181 at the beginning of 2023. Since then, SYNC stock has decreased by 16.6% and is now trading at GBX 151.
View the best growth stocks for 2023 here.
What other stocks do shareholders of Syncona own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syncona investors own include Rexahn Pharmaceuticals (REXN), Barrick Gold (ABX), Agnico Eagle Mines (AEM), Franco-Nevada (FNV), Goldex Resources (GDX), VanEck Gold Miners ETF (GDX), Goldcorp (GG), Barrick Gold (GOLD) and Northern Dynasty Minerals (NAK).
What is Syncona's stock symbol?: Syncona trades on the London Stock Exchange (LON) under the ticker symbol "SYNC."

How do I buy shares of Syncona?: Shares of SYNC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Syncona's stock price today?: One share of SYNC stock can currently be purchased for approximately GBX 151.
How much money does Syncona make?: Syncona (LON:SYNC) has a market capitalization of £1.01 billion and generates £229.94 million in revenue each year. The company earns £212.36 million in net income (profit) each year or GBX 0.32 on an earnings per share basis.
How can I contact Syncona?: Syncona's mailing address is Trafalgar Court, Les Banques, PO Box 255, ST PETER PORT, GY1 3QL, Guernsey. The official website for the company is www.bacitltd.com. The company can be reached via phone at 17168531362.

This page (LON:SYNC) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial